OBJECTIVES The aim of this study was to identify differences in survival on the basis of type of heart disease while awaiting orthotopic heart transplantation (OHT).
T here are few studies comparing the survival of patients with different types of heart disease. Prognosis and the optimal timing to waitlist patients with advanced heart failure for orthotopic heart transplantation (OHT) are especially important among cohorts not easily rescued with inotropes or mechanical circulatory support. Studies have shown that patients with congenital heart disease (CHD) have higher 2-month mortality on the waiting list after multivariate analysis compared with patients without CHD (1) and no survival benefit with ventricular assist device (VAD) support (2) .
Patients with restrictive cardiomyopathy (RCM) may also be at a disadvantage (3), because VAD support is often not possible with small ventricular cavities. In addition, there is concern that patients with hypertrophic cardiomyopathy (HCM) may have a poor prognosis and may not qualify for high-priority transplantation on the basis of the current allocation system (4) . In a national study analyzing survival among patients removed from the heart transplant waiting list, HCM and RCM were among the highest predictors of death (5) .
The goal of this study was to evaluate whether the type of heart disease affects mortality while awaiting OHT. Because OHT is a competing outcome, differences in rate of transplantation, United Network for Organ Sharing (UNOS) status at time of transplantation, and use of VAD support were also evaluated. The cohort included all adult patients registered on the national heart transplant waitlist between January 1, 2004 , and September 3, 2014.
METHODS SCIENTIFIC REGISTRY OF TRANSPLANT RECIPIENTS.
We used data from the Scientific Registry of Trans- there are outliers (6) .
PATIENT POPULATION AND UNOS STATUS.
We included all adult patients in the SRTR database placed on the waiting list for heart transplantation from January 1, 2004 , to September 3, 2014. Patients <18 years of age were excluded because UNOS criteria for listing pediatric patients differed from those for adults (7) .
Primary diagnosis was the principal explanatory variable and was categorized on the basis of definitions in the SRTR database: dilated cardiomyopathy (DCM), RCM (idiopathic, amyloid, endocardial fibrosis, sarcoidosis, radiation-or chemotherapyinduced heart disease, and other), ischemic cardiomyopathy (ICM), HCM, valvular heart disease, CHD, and "other" (1,216 prior heart transplantations and 312 "other" diagnoses).
UNOS status was at the time of listing for heart transplantation. UNOS status 1A (high priority) includes patients requiring intra-aortic balloon pumps Waitlist survival analysis on the basis of type of heart disease was performed using the Kaplan-Meier method, with censoring for OHT. The primary analysis was based on intention to treat, such that deaths following removal from the waiting list were included in the primary analysis. Multivariable Cox proportional hazards models were created to compare type of 
Mortality on Heart Transplant Waiting List S E P T E M B E R 2 0 1 6 : 6 8 9 -9 7 heart disease with DCM to evaluate differences in survival. The proportional hazards assumption for Cox models was evaluated using the proportionality test in proportions of missingness were excluded from the model, including peak oxygen consumption (65% missingness) and antiarrhythmic agents (21% missingness). For multiple imputation, we assumed that data were missing at random. We used the SAS procedure PROC MI and generated 5 models with imputed data followed by use of PROC MIANALYZE to evaluate parameter estimates and measures of variability. As a sensitivity analysis, we generated models excluding patients with VADs at the time of listing to evaluate whether the association of primary diagnoses with outcomes was similar to the model with the entire study population. All analyses were performed using SAS version 9.4. A p value #0.05 was considered to indicate statistical significance. UNOS status at the time of listing varied among the different heart diseases ( Table 1) . The majority of patients with DCM, ICM, or valvular heart disease were initially listed at the highest priority (UNOS statuses 1A (10) 52 (9) 105 (18) 82 (9) 247 (16) Hispanic 1,260 (9) 36 (4) 757 (6) 35 (6) 51 (9) 55 (6) 125 (8) Other 536 (4) 21 (3) 452 (4) 26 (4) 32 (5) 32 (3) (9) 56 (9) 63 (11) 185 (19) 188 (12) Other 857 (6) 36 (4) 635 (5) 25 (4) 24 (4) 43 (4) 63 (4) BMI, kg/m 2 14-19 734 (5) 46 (6) 266 (2) 35 (6) 46 (8) 138 (14) 97 (6) (26) 142 (24) 83 (14) 163 (17) 316 (21) 35-40 1,514 (10) 43 (5) 974 (8) 38 (6) 25 (4) 45 (5) 118 (8 and 1B). In contrast, the majority of patients with RCM, HCM, and CHD were initially listed at the lowest priority (UNOS status 2). About 50% of those patients with "other" heart diseases were listed as UNOS status 1, and 50% were listed as UNOS status 2. Table 1 ). As a sensitivity analysis, we excluded patients with VADs, and qualitative results were similar to those shown in Table 2 . There was an interaction between sex and type of cardiomyopathy ( Figure 2) , with women at higher risk for death compared with men for ICM (p < 0.01) and "other" diagnoses (p ¼ 0.03) and lower risk for death compared with men for RCM (p ¼ 0.048).
HEART TRANSPLANTATION. The rate of heart transplantation was highest among patients with RCM or HCM and lowest among those with CHD or "other" 
Heart Disease
Log-Rank p-value <0.0001
Kaplan-Meier survival curves while awaiting orthotopic heart transplantation (OHT) according to type of heart disease, with censoring at time of heart transplantation. CHD ¼ congenital heart disease; DCM ¼ dilated cardiomyopathy; HCM ¼ hypertrophic cardiomyopathy; ICM ¼ ischemic cardiomyopathy; other ¼ 1,216 prior heart transplantations and 312 "other" types of heart failure; RCM ¼ restrictive cardiomyopathy; valvular ¼ valvular heart disease. Abbreviations as in Table 1 .
types of heart disease ( Figure 3) . More than 50% of the study cohort underwent OHT at the conclusion of the study (see Table 3 for data stratified by heart disease).
Among the different heart diseases, patients with CHD
were less likely to undergo transplantation than those The risk of being female or male with a given type of heart disease while awaiting heart transplantation was assessed by multivariate Cox proportional hazard analyses adjusting for sex, age, race, insurance, body mass index, ABO blood type, hypertension, era, tobacco use, diabetes mellitus, malignancy, prior cerebral vascular accident, peripheral vascular disease, dialysis, estimated glomerular filtration rate, albumin, mean pulmonary arterial pressure, cardiac index, implantable cardioverter-defibrillator, mechanical ventilation, intra-aortic balloon pump, extracorporeal membrane oxygenation, ventricular assist device, total artificial heart, and inotropes. The analyses also included possible interactions between female sex and type of heart disease. CI ¼ confidence interval; HR ¼ hazard ratio.
Hsich et al.
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RCM. ECMO was rarely used to bridge patients to transplantation but more likely to be used among those with CHD and "other" types of heart disease.
Few patients had mechanical ventilation at the time of transplantation, with those with CHD or "other" diagnoses more likely than those with DCM, RCM, ICM, HCM, or valvular disease.
DISCUSSION
In a large, national transplantation registry, we found differences in adult survival on the basis of type of heart disease while awaiting cardiac transplantation.
After adjustment for possible confounding variables, RCM, CHD, and "other" types of heart disease were associated with the highest risk of death compared with DCM. Patients with HCM had a better prognosis but still worse than those with DCM and ICM. There was an interaction between sex and type of heart disease, with women compared with men at higher risk for death with ICM and "other" diagnoses and lower risk for death with RCM.
Our research is the first to document differences in adult outcomes on the basis of type of cardiomyopathy while awaiting heart transplantation. The results for adults with RCM are similar to those in pediatric patients (8) . Poor survival among patients with heart diseases such as RCM, CHD, and "other" types may be due to differences in the underlying disease or in the ability to rescue patients with inotropes and permanent mechanical circulatory support while they wait for transplantation. The rate of heart transplantation Time to heart transplantation among patients on the waiting list, with data stratified by type of heart disease. Abbreviations as in Table 1 . (11) 53 (14) 28 (5) 132 (12) RVAD AE LVAD or unspecified 786 (8) 15 (3) 544 (7) 18 (4) 16 (4) 19 ( (4) 59 (5) Values are n (%). *n < 10 patients.
Abbreviations as in Table 1 .
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Mortality on Heart Transplant Waiting List may also have contributed to the higher mortality rate among patients with CHD and "other" types of disease, but not those with RCM.
The current heart transplant allocation system is Lack of prophylactic ICDs may be due to few heart transplantation patients qualifying for these devices at the time of listing, because current guidelines for prophylactic ICDs are based on "native hearts" with moderate to severe systolic dysfunction (14) . Finally, the slow rate of transplantation in this subgroup may have been due to sensitization (suspected but not proved) and/or failure to meet criteria for highpriority status even when ill.
Patients with CHD have been known to constitute a high-risk group while awaiting heart transplantation.
Studies have shown that patients with CHD are more likely than those without CHD to be listed at lower status, less likely to receive mechanical circulatory support at the time of listing, less likely to have ICDs, and less likely to undergo heart transplantation (15).
Waiting times are significantly longer for patients with CHD compared with those with other diagnoses, which may be related to lower UNOS status at the time of listing and/or sensitization due to blood transfusions during prior surgical procedures (15) (16) (17) . Poor prognosis on the heart transplant waiting list and slower rates for heart transplantation are therefore not unexpected.
Patients with HCM awaiting OHT have better outcomes than those with most other types of cardiomyopathy, including RCM, which is contrary to the popular belief that this is a disadvantaged group with the current allocation system (4). HCM was once considered a rare disease with a high mortality rate but now is known to be among the most common CHDs, with an adult annual mortality rate of about 0.5% and a "burned-out" phase occurring in 3% of the HCM population. The risk for sudden death is greatest in patients <30 years of age and is reduced with the use of ICDs (18) . Because our HCM cohort had a mean age of 46 AE 14 years, they were at lower risk for sudden death. This risk was further reduced with 80% of the cohort having ICDs at the time of listing.
STUDY LIMITATIONS. The validity of the information is dependent on the accuracy of data entry. To reduce human error, SRTR data are assessed by edit checks, validation of data at the time of entry, and internal verification when there are outliers (6) . Despite these attempts, critical data such as the type of heart disease may be inaccurate because of misdiagnosis, difficulty with classification when more than 1 diagnosis is known, and failure to standardize the criteria for each subgroup. Misdiagnosis is unlikely to occur with coronary artery disease or CHD. However, it is possible to occur with HCM, because thickening of the ventricle may arise from hypertension or infiltrative diseases. Hypertensive heart disease is more common among blacks and women (19, 20) , but in our cohort, the HCM subgroup was predominately male (62% men, 38% women), and few were black (9%), making it less likely that a substantial number of patients Hsich et al. with hypertensive heart disease were misdiagnosed with HCM. Infiltrative diseases such as RCM could be mislabeled as HCM. However, the baseline characteristics, including age, for RCM and HCM were very different, as were outcomes, suggesting no significant overlap between the groups. The RCM group may have been mislabeled in the idiopathic and "other"
categories, but this is unlikely for the diagnoses of amyloidosis, endocardial fibrosis, sarcoidosis, and radiation-or chemotherapy-induced heart disease.
Standardizing the criteria for all heart disease and requesting pathology data post-transplantation will improve accuracy in the future.
CONCLUSIONS
Our research demonstrates a higher mortality rate in the United States for patients awaiting OHT on the basis of etiology of heart disease and sex. Patients with RCM, CHD, or prior heart transplantation had a higher risk for death than those with DCM, ICM, HCM, or valvular heart disease. The current heart allocation system does not address these differences. A revised heart allocation scheme has been proposed that will recognize these subgroups and should account for the disadvantaged.
KEY WORDS cardiac amyloidosis, cardiomyopathy, congenital heart disease, heart failure, heart transplantation, hypertrophic cardiomyopathy APPENDIX For a supplemental TRANSLATIONAL OUTLOOK: Our data support a change in the allocation system to prioritize RCM, CHD, and prior heart transplantation over the other types of heart disease. More research is needed to further define the risk factors for these subgroups.
